Market revenue in 2023 | USD 218.6 million |
Market revenue in 2030 | USD 395.5 million |
Growth rate | 8.8% (CAGR from 2023 to 2030) |
Largest segment | Mammalian source |
Fastest growing segment | Mammalian Source |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Microbial Source, Mammalian Source, Other Source |
Key market players worldwide | WuXi Biologics (Cayman) Inc, FUJIFILM Holdings Corp, AGC Biologics, Thermo Fisher Scientific Inc, Curia, Genscript Biotech Corp Class H, Boehringer Ingelheim Pharma, Abzena, JSR Corp, Bionova Scientific |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biologics contract development market will help companies and investors design strategic landscapes.
Mammalian source was the largest segment with a revenue share of 56.86% in 2023. Horizon Databook has segmented the Spain biologics contract development market based on microbial source, mammalian source, other source covering the revenue growth of each sub-segment from 2018 to 2030.
Spain has a history of high-quality clinical research, which is growing further. The public sector in the country has experienced a decline in research investments and is, therefore, lagging the EU average in innovation index.
A new draft of the Spanish Law for Clinical Trials was issued in April 2014 to reduce the number of regulatory approval steps as well as costs required for approval of clinical trials, simplifying procedures & reducing bureaucracy without jeopardizing patient safety and security.
Spain is being named as one of the prominent countries for conducting clinical trials due to the presence of highly experienced research centers and investigators, proven research quality, high patient recruitment volumes, and quick study start-up. All the above factors are expected to aid in market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain biologics contract development market, including forecasts for subscribers. This country databook contains high-level insights into Spain biologics contract development market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account